Intercell AG


@@start.t1@@--------------------------------------------------------------------------------   ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for   the content of this announcement. --------------------------------------------------------------------------------@@end@@

Intercell AG was honoured with the first price in the final round of the Biotechnica Award 2006 during yesterday’s ceremony at the Biotech CEO Conference in Zürich. The Biotechnica Award, endowed with 40,000 Euros, is awarded by the Deutsche Messe AG for the fourth time to European biotech and life science companies in the fields of biotechnology and related life sciences with proven success in launching innovative products or services, or in implementing promising new business concepts.

The jury including experts from science and industry as well as representatives of the capital markets, has selected three finalists from 16 outstanding candidates from eight countries in the first round. Alongside scientific innovation, the jury was judging criteria such as commercial viability, market relevance, marketing concepts and business models.

The 2nd price was awarded to Genmab S/A, a biotechnology company located in Denmark, and the 3rd prize was awarded to the German biotech company amaxa GmbH.

Conditions for Applicants:

@@start.t2@@•          Market presence of at least two years
•          At least 30 to 350 employees (maximum)
•          Annual turnover of up to 50 million euros
•          Independent business (maximum 25 percent share of company capital held
            by large company, except for venture-capital companies)
•          Successful activities on the biotechnology/life sciences markets@@end@@

For more information, please visit:

@@start.t3@@end of announcement                                                 euro adhoc 13.10.2006 08:21:21

ots Originaltext: Intercell AG
Im Internet recherchierbar:

Further inquiry note:
Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303

Branche: Biotechnology
ISIN:      AT0000612601
WKN:        A0D8HW
Börsen:  Wiener Börse AG / official market

Weitere Meldungen: Intercell AG

Das könnte Sie auch interessieren: